A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Required: MS4A1 overexpression (CD20+)

relapsed CD20+ Follicular Lymphoma grade 1-3a

Required: MS4A1 overexpression (CD20+)

relapsed CD20+ diffuse large B-cell lymphoma

Must have received: any prior therapy

Evidence of progression or lack of response following at least 1 prior treatment

Cannot have received: antibody-drug conjugate (polatuzumab vedotin)

Prior treatment with polatuzumab vedotin

Cannot have received: CD20-directed bispecific antibody (mosunetuzumab)

Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies

Cannot have received: antibody-drug conjugate (tafasitamab)

Prior treatment with tafasitamab and/or lenalidomide

Cannot have received: immunomodulatory agent (lenalidomide)

Prior treatment with tafasitamab and/or lenalidomide

Cannot have received: autologous stem cell transplant

Exception: within 100 days prior to first study treatment administration

Autologous SCT within 100 days prior to first study treatment administration

Cannot have received: CAR-T cell therapy

Exception: within 30 days before first study treatment administration

Prior CAR-T therapy within 30 days before first study treatment administration

Cannot have received: allogeneic stem cell transplant

Prior allogeneic SCT

Cannot have received: solid organ transplant

Prior solid organ transplantation